Business Wire

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Share

Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous coronary intervention (PCI) patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005049/en/

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump

Impella ECP is the world’s smallest heart pump. It achieves peak flows greater than 3.5 L/min and is delivered though a slender-profile sheath. It is un-sheathed in the descending aorta and expands to approximately 18 Fr. Using a specially designed pigtail, it crosses the aortic valve without a wire, and pumps from inside the ventricle. When the procedure is complete, the pump is re-sheathed back down to 9 Fr and removed with that same profile.

A unique design feature of Impella ECP is that it sits across the valve with a soft atraumatic polyurethane cannula that opens only when the pump is flowing. If the pump stops for any reason, this cannula relaxes allowing the valve leaflets to close around it, maintaining valve competency. Impella ECP is intended for short-term mechanical support in patients undergoing a high-risk PCI, to provide both circulatory support and left ventricular unloading.

For interventional cardiologists, vascular access and closure are critical to the success of PCI procedures with mechanical circulatory support. Typically, these procedures require placement of sheaths or cannulas ranging from 13-24 Fr to perform the intervention. Impella ECP allows for a smaller access site, which may increase adoption.

“We are excited about the benefits of this new breakthrough technology, which advances the field of heart recovery,” said Michael R. Minogue, Abiomed’s Chairman, President, and Chief Executive Officer. “Abiomed is making significant investments to develop smaller, smarter, and more connected technology that forms the foundation of the company’s continued leadership in the field of mechanical circulatory support.”

The prospective, multi-center, non-randomized early feasibility study will allow Abiomed, the study investigators, and the FDA to make qualitative assessments about the safety and feasibility of Impella ECP use in high-risk patients. The primary endpoint of the study is successful delivery, initiation and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI. The study protocol will enroll and treat up to five U.S. patients who require revascularization. If successful, enrollment will be expanded to additional patients, pending FDA approval. Study investigators will begin patient enrollment later this calendar year for the first-in-human trial.

Impella ECP is available for investigational use only and is not approved for use outside of clinical studies.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® devices are U.S. FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5™ with Smart Assist® are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery. The Impella RP is also authorized for emergency use by healthcare providers (HCP) in the hospital setting for providing temporary right ventricular support for up to 14 days in critical care patients with a body surface area ≥1.5 m2, for the treatment of acute right heart failure or decompensation caused by complications related to Coronavirus Disease 2019 (COVID‐19), including pulmonary embolism (PE). The Impella RP has neither been cleared or approved for the treatment of acute right heart failure or decompensation caused by complications related to COVID-19. The Impella RP has been authorized for the above emergency use by FDA under an EUA and has been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5™ with Smart Assist® is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia.

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit www.impella.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

Abiomed, Impella, Impella 2.5, Impella 5.0, Impella 5.5, Impella LD, Impella CP, Impella RP, SmartAssist and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella ECP, CVAD Study and STEMI DTU Study are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with the scope, scale and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Contact information

Sarah Karr
Communications Manager
978-882-8211
skarr@abiomed.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nexeo Plastics Signs Distribution Agreement in Europe with Kingfa20.10.2020 16:06:00 CESTPress release

Nexeo Plastics, a leading global thermoplastics resin distributor, has signed an agreement with Kingfa to distribute their engineering thermoplastic products throughout Europe. Effective immediately, Nexeo Plastics will carry and distribute Kingfa’s locally made compounds. Each product group offers a wide range of color-matching options and innate characteristics to improve manufacturing and end-product functionality. This includes an array of choices in unfilled, talc-filled, reinforced, toughened, flame-retardant and recycled compounds. “We look forward to partnering with Nexeo Plastics to expand our footprint in Europe and reach new customers who are seeking high-quality, customized compounding solutions,” said Dr. D.H. Sun, managing director of Kingfa Europe. Kingfa, a preeminent leader in the research, production and sales of advanced polymer materials, has European facilities in Wiesbaden, Germany, serving the EMEA region. The location includes an advanced technology production p

Brookfield Renewable Ireland Selects PCI’s Enterprise Cloud Platform to Meet its Energy Billing Requirements20.10.2020 16:00:00 CESTPress release

Brookfield Renewable Ireland has selected PCI’s Enterprise Platform for management of its energy billing requirements in the Irish power market. As part of its agreement with Brookfield Renewable Ireland, PCI will deploy its specifically tailored, cloud-based, integrated platform that incorporates the PCI Billing Solution, and a breadth of capabilities including: Management of complex bilateral contracts, such as power purchase agreements (PPA) Contract settlements calculation engine to perform settlement allocation based on specific business rules Interfaces with upstream and downstream systems Comprehensive auditability with all data versions and updates stored for auditing requirements Extensive workflow automation for invoice creation and management Data extraction, reporting and drill-down capabilities Platform extension to support Brookfield Renewable Ireland’s customer portal Chief Commercial Officer at Brookfield Renewable Ireland, Ciaran O'Brien noted, “To support our business

Goldman Sachs Merchant Banking Division Partners With Leading Data Infrastructure Management Team and Commits up to $500 Million to Form Data Center Platform, Global Compute20.10.2020 16:00:00 CESTPress release

The Goldman Sachs Merchant Banking Division (“GS MBD”) today announced that it has partnered with a seasoned management team, led by long-time data center industry executive Scott Peterson, to form Global Compute Infrastructure LP (“Global Compute” or the “Company”), a newly established global data center infrastructure platform. GS MBD has initially committed to fund up to $500 million of equity capital, primarily from its infrastructure fund, West Street Infrastructure Partners III, LP (“WSIP III”), to enable approximately $1.5 billion in near-term investments deployed across North America, Europe, Asia Pacific and Latin America. Global Compute intends to grow through a combination of acquisitions and organic development to serve customers in geographies with strong secular tailwinds and potential for significant data infrastructure growth. Leveraging the experience and track record of the management team, Global Compute will focus on acquiring and developing facilities which can mee

Andersen Global Signs Collaboration Agreement with Belarus’ Largest Law Firm20.10.2020 15:30:00 CESTPress release

Andersen Global expands its platform in Eastern Europe with the addition of collaborating firm REVERA, one of the top tier law firms in Belarus, broadening the organization’s coverage as it bolsters its foothold in the region. Founded in 1998, the Minsk-based firm provides corporate, commercial, litigation, labor, antitrust, real estate and intellectual property law, focusing on tax and private client services. Led by Managing Partner Dmitry Arkhipenko, REVERA’s team of more than 50 lawyers represents a number of multinational companies and often participates in Belarus’ legislative process. Additionally, the firm has been recognized by Chambers Europe, Legal 500, IFLR 100 and Best Lawyers. “For over 20 years, our firm has built a respectable reputation through our commitment to stewardship and independence, and our ability to provide clients with best-in-class solutions,” Dmitry said. “We look forward to working with the member firms and collaborating firms of Andersen Global as we co

The 26 th China Yiwu International Commodities (Standards) Fair to Kick Off This Month With More Activities to Promote Trade20.10.2020 15:21:00 CESTPress release

The 26th China Yiwu International Commodities (Standards) Fair ("Yiwu Fair") will be held at Yiwu International Expo Center on October 21-25, 2020. Founded in 1995 and as one of the three export exhibitions sponsored by China’s Ministry of Commerce, Yiwu Fair is now the largest, most influential, and most effective daily necessities exhibition in China. Yiwu Fair 2020 will be China’s first large-scale foreign trade exhibition presented both online and offline in the wake of the pandemic. It is expected to attract more than 50,000 professional buyers, with 3,400 international standard booths, covering hardware, electromechanical facilities, electronic & electrical appliances, daily necessities, crafts & ornaments, stationery & office goods, toys, sporting & outdoor products, knitwear, and gift packaging. This year, Yiwu Fair will invite around 10 delegations or 1,600 persons from foreign trade organizations and representative offices based in China, and nearly 20 delegations or 1,800 bu

Loomis Sayles Chief Investment Officer Jae Park Set to Retire in 2021; Deputy Chief Investment Officer David Waldman Named Successor20.10.2020 15:05:00 CESTPress release

Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Jae Park, executive vice president, member of the board of directors and chief investment officer, will retire on March 31, 2021 after 19 years with the company. David Waldman, executive vice president, member of the board of directors and deputy chief investment officer, will succeed Jae in the position of chief investment officer (CIO) at the time of Jae’s retirement. Jae and David have partnered in their oversight of Loomis Sayles’ investment platforms and infrastructure since David was named Loomis Sayles’ first deputy CIO in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005226/en/ Loomis Sayles Chief Investment Officer Jae Park set to retire in 2021. (Photo: Business Wire) “David is the ideal successor to Jae; they have been longtime partners responsible for overseeing Loomis Sayles’ investment and research teams and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom